Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
Sponsor: Adneuris Therapeutics, Inc.
Summary
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.
Official title: A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2026-09
Completion Date
2027-06
Last Updated
2026-10-19
Healthy Volunteers
No
Interventions
Cebranopadol
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
Cebranopadol
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
Placebo
Administration orally twice daily on Day 1 and 2.
Locations (2)
001127
North Canton, Ohio, United States
00113
Houston, Texas, United States